Related references
Note: Only part of the references are listed.Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: a randomized, double-blind, active-controlled, parallel group, multinational clinical trial
S. A. Ross et al.
DIABETES OBESITY & METABOLISM (2015)
AACE Comprehensive Diabetes Management Algorithm 2013
Alan Garber et al.
Endocrine Practice (2015)
Quantifying the Effect of Metformin Treatment and Dose on Glycemic Control
Jennifer A. Hirst et al.
DIABETES CARE (2012)
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Silvio E. Inzucchi et al.
DIABETES CARE (2012)
Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study
T. Haak et al.
DIABETES OBESITY & METABOLISM (2012)
Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension
R. Gomis et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2012)
Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study
M. -R. Taskinen et al.
DIABETES OBESITY & METABOLISM (2011)
Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks
A. Pfuetzner et al.
DIABETES OBESITY & METABOLISM (2011)
A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents
L. Olansky et al.
DIABETES OBESITY & METABOLISM (2011)
The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus
C. Reasner et al.
DIABETES OBESITY & METABOLISM (2011)
Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes
D. Williams-Herman et al.
DIABETES OBESITY & METABOLISM (2010)
Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study
Bernard Zinman et al.
LANCET (2010)
Impact of Metformin-Induced Gastrointestinal Symptoms on Quality of Life and Adherence in Patients with Type 2 Diabetes
Hermes Florez et al.
POSTGRADUATE MEDICINE (2010)
Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study
Debora Williams-Herman et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial
M. Jadzinsky et al.
DIABETES OBESITY & METABOLISM (2009)
Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus
E. Bosi et al.
DIABETES OBESITY & METABOLISM (2009)
Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study
P Weissman et al.
CURRENT MEDICAL RESEARCH AND OPINION (2005)
Gastrointestinal tolerability of extended-release metformin tablets compared to immediaterelease metformin tablets: results of a retrospective cohort study
L Blonde et al.
CURRENT MEDICAL RESEARCH AND OPINION (2004)
Share Paper
